These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21132257)

  • 21. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
    Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
    Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Helicobacter pylori positive infected patients according to Clarithromycin resistant 23S rRNA, rpl22 associated mutations and cyp2c19*1, *2, *3 genes pattern in the Early stage of Gastritis.
    Maghami AA; Mobarez AM; Yadegar A; Nikkhah M; Sadeghi A; Esmaeili S
    BMC Res Notes; 2022 Oct; 15(1):335. PubMed ID: 36284359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
    Kang JM; Kim N; Lee DH; Park YS; Kim JS; Chang IJ; Song IS; Jung HC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1287-91. PubMed ID: 18637061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers.
    Aoyama N; Tanigawara Y; Kita T; Sakai T; Shirakawa K; Shirasaka D; Kodama F; Okumura K; Kasuga M
    J Gastroenterol; 1999; 34 Suppl 11():80-3. PubMed ID: 10616772
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
    Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
    Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
    Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
    Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
    Miehlke S; Schneider-Brachert W; Kirsch C; Morgner A; Madisch A; Kuhlisch E; Haferland C; Bästlein E; Jebens C; Zekorn C; Knoth H; Stolte M; Lehn N
    Helicobacter; 2008 Feb; 13(1):69-74. PubMed ID: 18205669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microarray-Based Detection and Clinical Evaluation for
    Song Y; Dou F; Zhou Z; Yang N; Zhong J; Pan J; Liu Q; Zhang J; Wang S
    Biomed Res Int; 2018; 2018():2684836. PubMed ID: 30276203
    [No Abstract]   [Full Text] [Related]  

  • 29. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.
    Okudaira K; Furuta T; Shirai N; Sugimoto M; Miura S
    Aliment Pharmacol Ther; 2005 Feb; 21(4):491-7. PubMed ID: 15710002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
    Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
    Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Importance of CYP2C19 genetic polymorphism in the eradication of Helicobacter pylori in north Indians.
    Chaudhry AS; Kochhar R; Kohli KK
    Indian J Med Res; 2009 Oct; 130(4):437-43. PubMed ID: 19942749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori.
    Furuta T; Shirai N; Kodaira M; Sugimoto M; Nogaki A; Kuriyama S; Iwaizumi M; Yamade M; Terakawa I; Ohashi K; Ishizaki T; Hishida A
    Clin Pharmacol Ther; 2007 Apr; 81(4):521-8. PubMed ID: 17215846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycinresistant and- sensitive cases.
    Aydin A; Onder GF; Akarca US; Tekin F; Tunçyürek M; Musoğlu A
    Turk J Gastroenterol; 2005 Dec; 16(4):203-6. PubMed ID: 16547848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
    Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori.
    Yang JC; Yang YF; Uang YS; Lin CJ; Wang TH
    Br J Clin Pharmacol; 2009 May; 67(5):503-10. PubMed ID: 19552744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of smoking and CYP2C19 genotypes on H. pylori eradication success.
    Suzuki T; Matsuo K; Sawaki A; Wakai K; Hirose K; Ito H; Saito T; Nakamura T; Yamao K; Hamajima N; Tajima K
    Epidemiol Infect; 2007 Jan; 135(1):171-6. PubMed ID: 16740190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The relationship between genetic polymorphism of CYP2C19 and the efficacy of
    Luo LL; Chen B; Shu XL; Zheng W; Long G; Jiang MZ
    Zhonghua Er Ke Za Zhi; 2023 Jul; 61(7):600-605. PubMed ID: 37385802
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
    Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
    Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
    Kuo CH; Wang SS; Hsu WH; Kuo FC; Weng BC; Li CJ; Hsu PI; Chen A; Hung WC; Yang YC; Wang WM; Wu DC
    Helicobacter; 2010 Aug; 15(4):265-72. PubMed ID: 20633187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes of Helicobacter pylori isolates influence the outcome of triple therapy.
    Ram M R; Teh X; Rajakumar T; Goh KL; Leow AHR; Poh BH; Mariappan V; Shankar EM; Loke MF; Vadivelu J
    J Antimicrob Chemother; 2019 Jan; 74(1):11-16. PubMed ID: 30403784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.